Obesity as a factor of vascular remodeling


Cite item

Full Text

Abstract

Role of obesity in vascular remodeling, both in general population and is special groups of patients. Risk factors and consequences of vascular remodeling in obesity are shown

References

  1. Despres J-P., Lemieux I., Bergeron J. et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008; 28: 1039-1049
  2. Toto-Moukouo JJ., Achimastos A., Asmar RG. et al. Pulse wave velocity in patients with obesity and hypertension. Am Heart J 1986; 112: 136-140.
  3. Wildman R., Mackey R., Bostom A. et al. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension 2003; 42: 468-473.
  4. Wildman R., Farhat G., Patel A. et al. Weight change is associated with change in arterial stiffness among healthy young adults. Hypertension 2005;45:187-192.
  5. Orr J., Gentile C., Davy B., Davy P. Large artery stiffening with weight gain in humans. Role of visceral fat accumulation. Hypertension 2008; 51:1519- 1524.
  6. Henry RM., Kostense PJ., Spijkerman AM. et al. Arterial stiffness increases with deteriorating glucose tolerance status: The Hoorn Study. Circulation 2003; 107: 2089-2095.
  7. Ferreira I., Snijder MB., Twisk JWR., et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and health longitudinal study. J Clin Endocrinol metab. 2004; 89: 2632-2639.
  8. Resnick L., Militianu D., Cunnings A. et al. Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat and in sity intracellular free magnesium. Hypertension 1997; 30: 654- 659.
  9. Sutton-Tyrrell K., Newman A., Simonsick EM., et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging and body composition. Hypertension 2001; 38:429-433.
  10. Amar J., Ruidavets JB., Chamontin B. et al. Arterial stiffness and cardiovascular risk factors in population-based study. J Hypertens 2001; 19: 381-387
  11. Kotsis V., Stabouli S., Papamichael C., Zakopoulos N. Impact of obesity in intima-media thickness of carotid arteries. Obesity 2006: 14: 1708-1715
  12. Комитет экспертов ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV пересмотр). Рекомендации ВНОК, 2009.
  13. McGrill HC Jr., McMahan CA., Herderick EE., et al. Obesity and atherosclerosis in young men. Circulation 2002: 105; 2712-2718.
  14. Cassidy AE., Bielak LF., Zhou Y., et al. Progression of subclinical coronary atherosclerosis: does obesity make a difference? Circulation 2005: 111; 1877-1882.
  15. Elkeles RS., Fehert MD., Flather MD., et al. The association of coronary calcium score and conventional cardiovascular risk factors in type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study). Diabet Med. 2004; 21 : 1129-1134.
  16. Yusuf S., Hawken S., Ounpuu S. et al. Obesity and the risk of myocardial infarction in 27000 paticipants from 52 countries: a case-control stidy. Lancet 2005; 366: 1640-1649.
  17. Terry RB., Stefanick ML., Haskell WL., Wood PD. Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thing fat. Metabolism 1991; 40: 733-740.
  18. Okura T., Nakata Y., Yamabuki K., Tanaka K. Regional body composition changes exhibit opposing effects on coronary heart disease risk factors. Arterioscler Thromb Vasc Biol. 2004; 24: 923-929.
  19. Garbriely I., Ma X., Yang X. et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002; 51: 2951-2958.
  20. Brochu M., Tchernof A., Turner A. et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism 2003; 52: 599-604
  21. Morricone L., Donati C., Hassan T. et al. Relationship of visceral fat distribution to angiographically assessed coronary artery disease: results in subjects with or without diabetes or impaired glucose tolerance. Nutr Metab Cardiovasc Dis.2002; 12: 275-283.
  22. Lear SA., Humphries KH., Kohli S. et al. Visceral adipose tissue, a potential risk factor for carotid atherosclerosis. Results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke 2007;38: 2422-2429
  23. De Michele M., Panico S., Iannuzzi A. et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Srtoke 2002; 33: 2923-2928
  24. Tanko LB., Bagger YZ., Alexandersen P. et al. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in eldery women. Circulation 2003; 107: 1626-1631.
  25. Safar M., Czernichow S., Blacher J. Obesity, arterial stiffness, cardiovascular risk. J Am Soc Nephrol. 2006: 17; S109-S111
  26. ter Maaten JC., Bakker SJ., Serne EH. et al. Insulin′s acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin′s acute effects on proximal tubular sodium reabsorption correlate with salt sensitivity in normal subjects. Nephrol Dial Transplant. 1999: 14; 2357-2363
  27. Alvarez GE., Beske SD., Ballard TP., Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536.
  28. Begum N., Song Y., Rienzie J., Ragolia L. Vascular smooth muscle cell growth and insulin regulation of mitogen-activated protein kinase in hypertension. Am J Physiol 1988; 275: C42-C49.
  29. Feener EP., King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 (Suppl 1): S9-S13.
  30. Arcaro G., Gretti A., Balzano S., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulations 2002; 105: 576-582.
  31. Zierman SJ., Melenovsky V., Kass DA. Mechanisms, pathophysiology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25: 932-94
  32. Mathieu P., Poirier P., Pibarot P., Lemieux I. et al. Visceral obesity: link among inflammation, hypertension and cardiovascular disease. Hypertension.2009; 53: 577-584.
  33. Pilz S., Scharnag H., Tiran B. et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab. 2006; 91: 2542-2547.
  34. Hufnagel B., Dworak M., Soufi M. et al., Unsaturated fatty acids isolated from human lipoproteins activate protein phosphatase type 2Cβ and induce apoptosis in endothelial cells. Atherosclerosis 2005; 180: 245-254.
  35. Steinberg HO., Paradisi G., Hook G. et al. Free fatty acid elevation impairs insulin-mediated vasodilatation and nitric oxide production. Diabetes 2000; 49: 1231-1238.
  36. Huang ZH., Reardon CA., Mazzone T. Endogenous apoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006; 55: 3394-3402.
  37. Yu Y-H., Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res. 2005; 96: 1042-1052.
  38. Ng TWK, Watts GF., Farvid MS et al. Adipocytokines and VLDV metabolism: independent regulatory affects of adiponectin, insulin resistance and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.
  39. Yang RZ., Lee MJ., Hu H. et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLos Med 2006; 3: e287
  40. O′Brein KD, Chait A. Serum amyloid A: the "other" inflomatory protein. Curr Atheroscler Rep. 2006; 8: 62-68.
  41. Berg AH., Scherer P. Adipose tissue, inflammation and cardiovascular disease. Circ. Res. 2005; 96: 939-949.
  42. Rajala MW, Qi Y., Patel HR. et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671- 1679.
  43. Yannakoulia M., Yiannakouris N., Bluher S., et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003; 88: 1730-1736.
  44. Lee JH, Chan JL., Yiannakouris N., et al. Circulating resistin levels are not associated obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant and diabetic subjects. J Clin Endocrinol Metab. 2003; 88: 4848- 4856.
  45. Reilly MP, Lehrke M., Wolfe ML., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulations 2005; 111: 932-939.
  46. Kunnary A., Ukkola O., Paivansalo M., Kesaniemi A. High plasma resistin level is associated with enchanced highly sensitivity C-reactive protein and leukocytes. J Clin Endocrinol Metab. 2006; 91: 2755- 2760.
  47. Verma S., Li SH., Wang CH. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulations 2003; 108: 736- 740.
  48. Jung HS., Park KH., Cho YM., et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006; 69: 76-85.
  49. Xu W., Yu L., Zhou W., Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun. 2006; 351: 376-382.
  50. Silswal N., Singh AK., Aruna B., et al. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NFκβ-dependent pathway. Biochem Biophys Res Commun. 2005; 334: 1092 - 1101.
  51. Singhal A., Farooqi IS., Cole TJ., et al. Influence of leptin on Arterial distensibility. Clinical Investigation and Reports A Novel Link Between Obesity and Cardiovascular Disease? Circulation. 2002;106:1919-1924.
  52. Reilly MP., Igbal N., Schutta M., et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 3872- 3878.
  53. Bodary PF., Gu S., Shen Y., et al. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprptein E-deficient mice. Atheroscler Thromb Vasc Biol. 2005; 25: 119-122.
  54. Stephenson K., Tunstead J., Tsai A., et al. Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Atheroscler Thromb Vasc Biol. 2003; 23: 2027-2033.
  55. Bouloumie A., Marumo T., Lafontan M., Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999; 13: 1231-1238.
  56. Quehenberger P., Exner M., Sunder-Plassmann R., et al. Leptin induces endotelin-1 in endothelial cells in vitro. Circ. Res. 2002; 90: 711-718.
  57. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis. Exploring the connection. Arterioscler Thromb Vasc Biol. 2007; 27: 996-1003
  58. Oda A., Taniguchi T., Yokoyama M. Leptin stimulates rat aortic smooth muscle cells proliferation and migration. Kobe J Med Sci. 2001; 47: 141-150.
  59. Nacata M., Yada T., Soejima N., Maruyama I. Leptin promotes aggregation of human platelets via the long from of its receptor. Diabetes 1999; 48: 462-429.
  60. Mangge H., Almer G., Haj-Yahya S. et al. Preatherosclerosis and adiponectin subfractions in obese adolescents. Obesity (2008) 16 12, 2578-2584.
  61. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23: 85-89.
  62. Maahs DM., Ogden LG., Kinney GL., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747-753.
  63. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa β signaling through a cAMP-dependent pathway. Circulation 2005; 111: 747-753.
  64. Motoshima H., Wu X., Mahadev K., Goldstein BJ. Adiponectin suppress proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315: 264-271.
  65. Wang Y., Lam KS., Xu JY., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005; 280: 18341-18347.
  66. Ouchi N., Kihara S., Arita T. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumalation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
  67. Wisse B.E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004: 15; 2792-2800
  68. Volf MC., Sladec R., Robitaille J., et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004; 12: 1217-1222
  69. Sharma A. Mediastinum fat, insulin resistance and hypertension. Hypertensi on 2004: 44; 117-118.
  70. Stompor T., Krasniak A., Sulowicz W.,et al. Changes in common carotid artery intima-madia thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant 2005: 20; 404-412.
  71. Yamauchi T., Kuno T., Takada H. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. Nephrol Dial Transplant 2003: 18; 1842-1847.
  72. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008: 23; 3041- 3046.
  73. Kats M., Hawxby AM, Barker J., Allon M. Impact of Obesity on arteriovenous fistula outcomes in dialysis patients. Kidney Int: 2007; 17: 39-43
  74. Allon M., Ornt DB., Schwab SJ et al. Factors associated with the prevalence of arteriovenous fistula in haemodialysis patients in the HEMO Study. Kidney Int 2000; 58: 2178-2175.
  75. Pisoni RL., Young EW., Dykstra DM. et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int: 2002; 1: 305 - 316.
  76. Weyde W., Krajewska M., Letachowicz W. et al. Obesity is not an obstacle for successful autogenous arteriovenous fistula creation in haemodialysis. Nephrol Dial Transplant 2008; 23(4):1318-1322
  77. Кутырина И.М., Руденко Т.Е., Швецов М.Ю., Кушнир В.В. Факторы риска сердечно-сосудистых осложнений на додиализной стадии хронической почечной недостаточности. Тер архив 2005; 5: 45-50.
  78. Porter CJ., Stavroulopoulos A., Roe SD., et al. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stage 3 and 4, with and without diabetes. Nephrol Dial Transplant 2007; 22: 3208-3213.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies